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NOR-1/NR4A3 is an “orphan member” of the nuclear
hormone receptor superfamily. NOR-1 and its close rel-
atives Nurr1 and Nur77 are members of the NR4A sub-
group of nuclear receptors. Members of the NR4A sub-
group are induced through multiple signal transduction
pathways. They have been implicated in cell prolifera-
tion, differentiation, T-cell apoptosis, chondrosarcomas,
neurological disorders, inflammation, and atherogene-
sis. However, the mechanism of transcriptional activa-
tion, coactivator recruitment, and agonist-mediated ac-
tivation remain obscure. Hence, we examined the
molecular basis of NOR-1-mediated activation. We ob-
served that NOR-1 trans-activates gene expression in a
cell- and target-specific manner; moreover, it operates
in an activation function (AF)-1-dependent manner. The
N-terminal AF-1 domain delimited to between amino
acids 1 and 112, preferentially recruits the steroid re-
ceptor coactivator (SRC). Furthermore, SRC-2 modu-
lates the activity of the AF-1 domain but not the C-
terminal ligand binding domain (LBD). Homology
modeling indicated that the NOR-1 LBD was substan-
tially different from that of hROR, a closely related
AF-2-dependent receptor. In particular, the hydropho-
bic cleft characteristic of nuclear receptors was re-
placed with a very hydrophilic surface with a distinct
topology. This observation may account for the inability
of this nuclear receptor LBD to efficiently mediate co-
factor recruitment and transcriptional activation. In
contrast, the N-terminal AF-1 is necessary for cofactor
recruitment and can independently conscript coactiva-
tors. Finally, we demonstrate that the purine anti-me-
tabolite 6-mercaptopurine, a widely used antineoplastic
and anti-inflammatory drug, activates NOR-1 in an AF-
1-dependent manner. Additional 6-mercaptopurine ana-
logs all efficiently activated NOR-1, suggesting that the
signaling pathways that modulate proliferation via in-
hibition of de novo purine and/or nucleic acid biosynthe-
sis are involved in the regulation NR4A activity. We
hypothesize that the NR4A subgroup mediates the geno-
toxic stress response and suggest that this subgroup
may function as sensors that respond to genotoxicity.
Nuclear hormone receptors (NRs)1 function as ligand-acti-
vated transcription factors that regulate gene expression in-
volved in reproduction, development, and general metabolism
(1). NRs function as the pipeline between physiology and gene
expression. The importance of NRs in human physiology is
underscored by the extensive range of therapeutics that has
been created to combat disorders associated with dysfunctional
hormone signaling. These diseases affect every discipline of
medicine (2). All members of the NR superfamily display a
highly conserved structural organization (1) with an amino-
terminal region AB (that encodes activation function 1 (AF-1)),
followed by the C-region that encodes the DNA binding domain
(DBD), a linker region D, and the C-terminal E region. The DE
region encodes the ligand binding domain (LBD) and a tran-
scriptional domain, denoted as activation function 2 (AF-2)
(1, 2).
A decade ago, gene products were identified that appeared to
belong to the nuclear receptor superfamily on the basis of their
nucleic acid sequence identity. The endogenous signaling mol-
ecules that bound to these proteins were unknown; thus, the
term “orphan receptor” was adopted. Based on members of the
nuclear receptor superfamily that have been more fully char-
acterized, the orphans forecast an enormous yet unexploited
opportunity for the discovery of important new therapeutic
agents.
The Nur77, NURR1, and NOR-1 (NR4A1–3 subgroup) family
of orphan NRs are well conserved in the DNA binding domain
(91–95%) and the C-terminal LBD (60%) but divergent in
the N-terminal AB region (e.g. AF-1).
The NR4A family members can bind as monomers and ho-
modimers to single/tandem copies of the nerve growth factor-
inducible response element (NBRE), AAAGGTCA, a variant
NR half-site, and constitutively regulate transcription. In ad-
dition to binding DNA as monomers, Nur77 and Nurr1 (but not
NOR-1) heterodimerize with RXR and mediate efficient trans-
activation in response to RXR-specific agonists from DR5 mo-
tifs. Moreover, a Nur response element has been found in the
promoter region of the pro-opiomelanocortin gene (POMC) that
is efficiently bound and transactivated by Nur and NOR-1
homodimers (3–8).
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This subgroup of proteins functions as immediate early/
stress response genes that are induced by a wide range of
physiological signals (9–13). They have been implicated in
proliferation, differentiation, apoptosis, hypertrophy/remodel-
ing, Parkinson’s disease, schizophrenia, manic depression,
atherogenesis, cancer, and autoimmune disease (14–34). In
itself, the NR4A1–3 subgroup presents an exciting scientific
challenge; unlocking the molecular mechanisms that mediate
NR4A-dependent transcription provides the platform for likely
pharmaceutical and therapeutic exploitation.
NOR-1, Nur77, and NURR1 have been shown to play a key
role in regulating expression of various genes in the hypotha-
lamic-pituitary-adrenal axis (35). Corticotropin-releasing hor-
mone treatment of adrenal and pituitary cells induces Nur77
and NOR-1. These events lead to the activation of the gene
encoding steroid 12-hydroxylase (36, 37). The Nur subfamily
also regulates steroid 17-hydroxylase and the 20-hydroxy-
steroid dehydrogenase promoters (36–38). Therefore, the
NR4A subgroup plays a role in steroidogenesis. Among other
genes that members of the NR4A subfamily regulate in the
hypothalamic-pituitary-adrenal axis are the pro-opiomelano-
cortin (POMC) gene, which is the precursor to adrenocortico-
tropic hormone, the chief regulator of adrenal steroidogenesis,
and the corticotropin-releasing hormone gene (5, 39, 40).
In response to inflammatory cytokines (e.g. interleukin-1
and tumor necrosis factor-), there is local up-regulation of
corticotropin-releasing hormone in rheumatoid arthritis (RA)
synovial tissue, indicating corticotropin-releasing hormone as a
component of the inflammatory cascade in arthritis. It has been
shown that the NR4A subgroup up-regulates corticotropin-
releasing hormone expression by interacting with specific cis-
acting sequences in its proximal promoter region. As such,
the NR4A family of proteins represents a potential target for
therapeutic intervention to control inflammatory responses
(25, 41, 42).
Gene targeting experiments have established a role for
NOR-1 and Nur77 in mediating T cell development. Nur77 and
NOR-1 are rapidly induced by the T-cell antigen receptor sig-
naling in immature thymocytes and T-cell hybridomas leading
to apoptosis (14–17, 44). Apoptosis represents an effective way
to eliminate cancerous cells, and a variety of evidence suggests
that the NR4A subgroup is involved in the regulation of apo-
ptosis in prostate, lung, gastric, breast, and colon cancer cells
(28–34). The NR4A subfamily is further implicated in carcino-
genesis by the finding that NOR-1 is involved in a chromosomal
translocation with the Ewing’s sarcoma gene identified in the
extraskeletal myxoid chondrosarcoma (45).
Activated smooth muscle cells are a hallmark of pathological
vascular processes, including atherosclerosis and restenosis
(46). It has been established that atheromatous lesions are
active sites of inflammation and immune responses, and cyto-
kines mediate the chronic development of atherosclerosis (47–
49). Recently, it has been shown that the NR4A subgroup is
expressed in human atherosclerotic lesions, and inhibition of
the NR4A subgroup subfamily transcription factors in smooth
muscle cells results in enhanced lesion formation, whereas
overexpression of Nur77/NOR-1/Nurr1 decreases neointimal
formation. Thus, the NR4A subgroup has a protective function
in the initiation and the progression atherogenesis (26, 27). The
importance of NOR-1 as a potential target for anti-cancer,
inflammation, and atherogenic drugs underscores the impor-
tance of understanding the NOR-1 molecular mechanism of
action. Hence, we used a variety of techniques to investi-
gate the critical subdomains and coactivators that mediate
its function.
In summary, we demonstrated that NOR-1-mediated tran-
scription and co-factor recruitment operated in an AF-1-de-
pendent manner; furthermore, the AF-1 domain was required
for NOR-1-dependent transactivation of target genes. In ac-
cordance with the role of NOR-1 in inflammation and carcino-
genesis, NOR-1 is activated by the anti-cancer and anti-inflam-
matory drug 6-mercaptopurine. Moreover, this thiopurine
agent specifically modulates the activity of the AF-1 domain.
EXPERIMENTAL PROCEDURES
Cell Culture and Transient Transfection—Proliferating C2C12 cells
and COS-1 cells were kept in DMEM supplemented with 20 and 10%
fetal calf serum, respectively, in 6% CO2. Cells grown in 12-well dishes
to 60–70% confluence were transiently transfected with 0.33–1 g of
pGL2b-tk-LUC (50) or pNBRE3-tk-LUC (6–8) or pPOMC-TK-LUC
(NurRE-5POMC-tk-LUC) (51) reporter plasmid together with 0.33–0.5
g of pSG5-NOR-1-FL or pSG5-NOR-1-CDE or pSG5-NOR-1-ABC or
pSG5 alone using a DOTAP/DOSPER (Roche Applied Science and Sci-
entifix) liposome mixture in HEBS (42 mM HEPES, 275 mM NaCl, 10
mM KCl, 0.4 mM Na2HPO4, 11 mM dextrose, pH 7.1) (total DNA 2–2.5
g/well). The DNA/DOTAP/DOSPER mixture was added to the cells in
1 ml of fresh DMEM containing 10% fetal calf serum and incubated for
14 h. Transfections in C2C12 with 0.33–1 g of pNBRE3-tk-LUC or
pPOMC-TK-LUC reporter plasmid together with 0.33–0.16 g of pSG5-
NOR-1-FL or pSG5-NOR-1-CDE, or pSG5-NOR-1-ABC or pCMX-
Nur-77 or pCMX-NURR1 (7) or pSG5 or pCMX alone in the presence or
absence of 6-mercaptopurine or 6-mercaptopurine riboside or 6-mercap-
topurine-2-deoxyriboside or 6-mercaptopurine monohydrate or 6-mer-
captopurine-9--D-ribofuranoside (50–100 M; Sigma) were performed
with phenol red-free DMEM containing 5% charcoal-stripped fetal calf
serum. The DNA/DOTAP/DOSPER mixture was added to the cells in 1
ml of fresh DMEM containing 5% charcoal-stripped fetal calf serum and
incubated for 14 h. Medium was replaced 16–24 h later, and/or 6-mer-
captopurine, 6-mercaptopurine riboside, 6-mercaptopurine-2-deoxyri-
boside, 6-mercaptopurine monohydrate, or 6-mercaptopurine-9--D-ri-
bofuranoside was added, and cells were grown for a further 24–48 h.
Cells were harvested after 48 h and were assayed for luciferase activity.
Each experiment represented at least two sets of independent tripli-
cates to overcome the variability inherent in transfection experiments
(52–56).
Luciferase Assays—Luciferase activity was assayed using a Luclite
kit (Packard) according to the manufacturer’s instructions. Briefly, cells
were washed once in PBS and resuspended in 150 l of phenol red-free
DMEM and 150 l of Luclite substrate buffer. Cell lysates were trans-
ferred to a 96-well plate, and relative luciferase units were measured
for 5 s in a Wallac Trilux 1450 microbeta luminometer (52–56).
GAL4 Hybrid Assays—C2C12 and COS-1 cells were passaged into
12-well plates and transfected at 50–80% confluence with 0.33–1 g of
reporter, G5E1b-LUC, and 0.33–0.16 g of GAL4DBD or GAL-NOR-1
chimeric constructs (GAL-NOR-1-FL, AB, DE, aa 1–150, aa 40–160, aa
200–292, aa 1–60, aa 1–112, and the GAL-chimeric constructs contain-
ing mutations in the AB region) and/or were co-transfected in the
presence and absence of pSG5-SRC-2 (0.33–0.1 g) using a DOTAP/
DOSPER liposome mixture in HEBS per well. Transfections were per-
formed in DMEM containing 10% fetal calf serum. Phenol red-free
DMEM containing 5% charcoal-stripped fetal calf serum was used for
transfections performed with NOR-1 GAL-chimeric constructs and
GAL4VP16, GAL-MEF2C, GAL-MEF2D, GAL-MyoD, GAL-Myogenin,
GAL-SRC-2, and GAL-p300Nter (50–52). These constructs were co-
transfected in the presence and absence of 6-mercaptopurine, 6-mer-
captopurine riboside, 6-mercaptopurine-2-deoxyriboside, 6-mercapto-
purine monohydrate, or 6-mercaptopurine-9--D-ribofuranoside (50–
100 M). After 16–24 h, the medium was replaced, and/or 6-MP
derivatives were added to cells. Cells were harvested 48 h after trans-
fection for the assay of luciferase activity. Each experiment represented
at least two sets of independent triplicates to overcome the variability
inherent in transfection experiments (52–56).
Plasmids and Primer Sequences—The expression plasmids GALO
(57), pSG5 (Stratagene), pCMX (58), pCMX-Nur77, and pCMX-NURR1
(7) and the reporter plasmids pNBRE3-tk-LUC (6–8), pPOMC-tk-LUC
(NurRE-5POMC-tk-LUC) (51), and G5E1b-LUC (59) have been described
elsewhere. Generation of full-length mouse NOR-1 was performed by
reverse transcriptase-PCR from muscle RNA with Pfu DNA polymerase
(Promega), using the manufacturer’s buffer. All PCR products were
cloned into the EcoRI site of pSG5 and then isolated after EcoRI diges-
tion and subsequently cloned into pGAL0 and pGEX4T1. The primers
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used for the synthesis of full-length mouse NOR-1 were GMUQ-720 5
(GCG GAA TTC ACC ATG CCC TGC GTG CAA GCC CAG) and
GMUQ-722 3 (GCG GAA TTC TCA GAA AGG CAG GGT GTC AAG
GAA). We then synthesized additional primers to subclone the DE, AB,
ABC, and CDE regions into pSG5 and GALO. The primers used for the
DE were GMUQ-724 5 (GCG GAA TTC ACC ATG GTT AAG GAA GTT
GTG CGT) and GMUQ-722 3. The primers used to synthesize the AB
region were GMUQ-720 5 and GMUQ-726 3 (GCG GAA TTC TCA
TGT GCC TTC CCC AGA TGA TGA). The primers used to synthesize
the ABC region were GMUQ-720 5 and GMUQ-733 3 (GCG GAA TTC
TCA CCC GAC ACT GAG ACA CTT CTG). The primers used to syn-
thesize the CDE region were GMUQ-732 5 (GCG GAA TTC ACC ATG
TGT GCC GTG TGC GGC G) and GMUQ-722 3.
We subsequently constructed various subdomains of the AB region
by PCR and cloned these segments into the EcoRI/SalI site of GAL4.
The NOR-1-AB-aa1–150 was subjected to PCR and cloned into SV40-
GAL0 using primers GMUQ-720 5 and GMUQ-756 3 (GCG GTC GAC
TCA GGG GAA GCC TGG AGT GG). The NOR-1-AB-aa40–160 region
was subjected to PCR and cloned into SV40-GAL0 using primers
GMUQ-758 (GCG GAA TTC ACC ATG GAC CTC GGT AGC ACG GG)
and GMUQ-759 3 (GCG GTC GAC TCA CTC GTC GTC CCA CAG
CG). The NOR-1-AB-aa150–292 region was subjected to PCR and
cloned into SV40-GAL0 using primers GMUQ-757 5 (GCG GAA TTC
ACC ATG CCC CCG CAG GCG GGG GC) and GMUQ-723 3. The
NOR-1-AB-aa1–60 region was subjected to PCR and cloned into SV40-
GAL0 using primers GMUQ-720 5 and GMUQ-760 3 (GCG GTC GAC
TCA GAA GGT ACT GAA GCT GGG). The NOR-1-AB-aa1–112 region
was subjected to PCR and cloned into SV40-GAL0 using primers
GMUQ-720 5 and GMUQ-761 3 (GCG GTC GAC TCA ATG GTG ATG
GTG GTG GTG G).
We then synthesized several primers for site-directed mutagenesis
and used the Stratagene QuikChange multisite-directed mutagenesis
kit as per the manufacturer’s instructions to produce GAL4-NOR-1-AB
chimeras that simultaneously carried double, triple, and quadruple
amino acid mutations. NOR-1-AB mutant primers were synthesized
and 5-phosphorylated by GENEWORKS. The primers made were S59A
T60A-GMUQ-800 5 (CTG CCC AGC TTC GCA GCC TTC ATG GAG
GGC), S59P T60P-GMUQ-801 5 (CTG CCC AGC TTC CCA CCC TTC
ATG GAG GGC), S142A T145A-GMUQ-803 5 (G TCT CCG CCG GCA
ACA CCG GCA ACT CCA GGC), and S142P T145P-GMUQ-804 5 (TCT
CCG CCG CCC ACA CCG CCC ACT CCA GGC).
GST Pull-downs—GST and GST fusion proteins were expressed in
Escherichia coli (BL21) and purified using glutathione-agarose affinity
chromatography as described previously (52–56). The GST fusion pro-
teins were analyzed on 10% SDS-PAGE gels for integrity and to nor-
malize the amount of each protein. The Promega TNT-coupled tran-
scription-translation system was used to produce [35S]methionine-
labeled NOR-1 and coactivator proteins that were visualized by SDS-
PAGE. In vitro binding assays were performed with glutathione-
agarose beads (Sigma) coated with 500 ng of GST fusion protein and
2–10 l of [35S]methionine-labeled protein in 200 l of binding buffer
containing 100 mM NaCl, 20 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5%
Nonidet P-40, 5 g of ethidium bromide, and 100 g of bovine serum
albumin. The reaction was allowed to proceed for 1–2 h at 4 °C with
rocking. The affinity beads were then collected by centrifugation and
washed five times with 1 ml of binding buffer without ethidium bromide
and bovine serum albumin. The beads were resuspended in 20 l of
SDS-PAGE sample buffer and boiled for 5 min. The eluted proteins
were fractionated by SDS-PAGE, and the gel was treated with Amer-
sham Amplify fluor, dried at 70 °C, and autoradiographed.
Molecular Modeling—We used molecular modeling as a tool to fur-
ther investigate the inability of the atypical nuclear receptor LBD to
interact with coactivators. The starting point for homology modeling
was the crystal structure of the human retinoic acid receptor  in a
complex with the retinoid Cd564 (Protein Data Bank number 1FCY).
Alignments were performed with ClustalV and adjusted manually
thereafter. Homology modeling was performed by satisfaction of spatial
restraints using the program Modeler 6 (60–62). The resulting model
was subjected to Ramachandran analysis and further quality checking
with the WhatIf suite of programs. Hydrophobicity analysis was per-
formed using the molecular modeling program SCULPT (60–62). An
LXXLL-containing peptide from a previously published thyroid hor-
mone receptor/steroid receptor coactivator peptide complex was super-
imposed onto both the retinoic acid receptor  (RAR) and NOR-1 LBDs,
enabling us to delineate a hypothetical coactivator binding interface.
De novo docking was carried out using the spherical polar Fourier
correlation program HEX (60–62). Briefly, a Protein Data Bank file
(COA1) was created from coactivator peptide atomic coordinates ex-
tracted from structure file 1FCY. COA1 and the NOR-1 model or RAR
were then iteratively docked and fractionally rotated in all six degrees
of freedom so that a total of 6.3  108 rotational combinations were
sampled. Note that coordinates for water molecules in the RAR struc-
ture were removed prior to docking.
RESULTS
NOR-1 Trans-activates Gene Expression in a Cell- and Re-
sponse Element-specific Manner—NOR-1 is expressed in skel-
etal muscle tissue and cells (63–65). We performed reverse
transcriptase-PCR experiments using total RNA extracted
from C2C12 skeletal muscle cells to isolate full-length mouse
NOR-1 cDNA. To verify the integrity of the cloned NR after
full-length sequencing, we examined the ability of NOR-1 to
trans-activate two NR4A-dependent reporters, NBRE-3-tk-
LUC (6–8) and the NurRE-5-tk-LUC (51). The NBRE-3-tk-
LUC reporter construct contains the NBRE derived from the
monomeric consensus binding site, AAAGGTCA, that was iden-
tified by genetic selection in Saccharomyces cerevisiae. This
plasmid contains three copies of a consensus binding site
(AAAGGTCA) cloned upstream of the heterologous herpes sim-
plex virus thymidine kinase (tk) promoter (6–8) linked to the
luciferase (LUC) gene. The NurRE-5POMC-tk-LUC reporter
contains five copies of the naturally occurring NR4A response
element (TGATATTTACCTCCAAATGCCA) from the POMC
gene. This native response element is responsive to physiolog-
ical stimuli, binds NR4A dimers, and is more responsive to
NR4A-mediated transactivation (5, 51).
We investigated the ability of NOR-1/NR4A3 to transacti-
vate the NBRE-3 and NurRE-5POMC reporters in muscle C2C12
and nonmuscle COS-1 cells in DMEM supplemented with 10%
fetal bovine serum. In control studies, C2C12 myogenic cells
and COS-1 cells were transfected with the control reporter
plasmid pGL2b-tk-LUC (lacking a response element in an
pGL2basic backbone) (50). NOR-1 expression plasmids did not
trans-activate the reporter backbone plasmid in either cell type
(Fig. 1, A and B). However, when C2C12 muscle cells and
COS-1 cells were cotransfected with the NOR-1 expression
vector and the reporter plasmid NBRE-3-tk-LUC, we observed
muscle-specific NOR-1-dependent trans-activation of the
NBRE-3 reporter (Fig. 1, C and D). NOR-1 also efficiently
trans-activated the NurRE-5POMC reporter in muscle cells (Fig.
1E). In contrast to the situation with the NBRE-3 reporter,
NOR-1 very efficiently and preferentially activated the NurRE-
5POMC reporter in COS-1 cells (Fig. 1F). In summary, the data
suggest NOR-1 trans-activated gene expression in a cell- and
response element (target)-specific manner.
Moreover, we investigated and compared the ability of
NOR-1 lacking the DE region, which encodes the LBD (e.g.
NOR-1-ABC construct encodes aa 1–379), and NOR-1 lacking
the AB region, which encodes the AF-1 domain (e.g. NOR-1-
CDE construct contains aa 293–627), to transactivate the
NBRE and NurRE-response elements in muscle and non-
muscle COS-1 cells (Fig. 1, C–F). Cell specificity has been found
to play an important role in the activity of the AF-1 and AF-2
domains in the estrogen, glucocorticoid, progesterone recep-
tors, and RARs (66, 67). The ability of different activation
functions 1 and 2 to operate has been found to vary in relation
to the cell line used and the spatio-temporal expression pat-
tern of the specific receptor, suggesting that cell-specific acti-
vation mechanisms are involved in the functioning of the
different AFs.
Surprisingly, deletion of the AB region that encodes the AF-1
domain (SG5-NOR-1-CDE) completed ablated the ability of
NOR-1 to trans-activate the NBRE-3 and NurRE-5POMC re-
porters in myogenic and COS-1 cells (Fig. 1, C–F). Hence, we
investigated whether the AB region could independently acti-
vate gene expression and/or operate in a cell-specific manner.
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C2C12 myogenic cells and COS-1 cells were co-transfected with
the SG5-NOR-1-ABC, expression vector, and pNBRE-tk-LUC
and NurRE-5POMC reporters. The NOR-1-ABC expression vec-
tor efficiently trans-activated the NBRE reporter in muscle
cells (Fig. 1C); however, its ability to trans-activate the NurRE-
5POMC reporter in muscle and nonmuscle cells was compro-
mised (Fig. 1, E and F). These experiments indicated that the
AB region that encoded the AF-1 domain was necessary for
optimal NOR-1-dependent transactivation of NBRE/NurRE-
5POMC-dependent reporters. Second, the LBD was necessary
for NOR-1-dependent transactivation of the NurRE-5POMC but
not the NBRE-3 reporter (Fig. 1, C, E, and F). Moreover, these
experiments suggest that the C-terminal LBD (DE) region of
NOR-1, unlike other orphan and classical nuclear receptors, is
not sufficient to mediate trans-activation of gene expression, in
contrast to the AF-1 domain, which can function in an inde-
pendent manner. These experiments demonstrate that NOR-1
functions in a cell- and target-specific manner.
The N-terminal AB Region of NOR-1 Encodes an Efficient
AF-1 Domain Located between Amino Acid Positions 1 and
FIG. 1. NOR-1 trans-activates gene expression in a cell- and response element-specific manner. A–F, SG5-NOR-1-FL, SG5-NOR-1-
CDE, and SG5-NOR-1-ABC (0.33 g) were co-transfected into C2C12 proliferating myoblasts and COS-1 cells together with the reporter genes 1
g of pGL2b-tk-Luc (A and B), NBRE-3-tk-Luc (C and D), or NurRE-5-tk-Luc (E and F), respectively. The AB (AF-1) region of NOR-1 is necessary
for agonist-independent and NOR-1-mediated transactivation of gene expression. AF-1 functions in a cell- and target-specific manner. C–F,
SG5-NOR-1-FL, SG5-NOR-1-CDE, and SG5-NOR-1-ABC (0.33 g) were co-transfected into C2C12-proliferating myoblasts and COS-1 cells
together with the reporter gene 1 g of NBRE-3-tk-Luc (C and D) or NurRE-5-tk-Luc (E and F). -Fold activation is expressed relative to luciferase
activity obtained after cotransfection of the pSG5 alone, arbitrarily set at 1. The mean luciferase -fold activation values and S.D. (bars) were derived
from a minimum of two or three independent triplicate experiments.
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112—To identify and further characterize the domains of
NOR-1 involved in transcriptional activation, we utilized the
GAL4 hybrid system, whereby putative activation domains are
fused to the DBD of the yeast transcription factor GAL4 (57). If
these regions encode modular activation domains, they comple-
ment the GAL4 DBD (to produce a functional trans-activator)
and induce the transcription of the GAL-responsive reporter
construct G5E1b-LUC, containing an E1b TATA box with five
17-mer GAL4 binding sites linked to the LUC reporter (59).
The system utilized an SV40 promoter expression vector
pGAL4-DBD (57) that contains a multiple cloning site down-
stream of the GAL 4 DBD. We fused NOR-1 and various do-
mains (e.g. AB or DE regions, etc.) of NOR-1 to the GAL 4 DNA
binding domain (Fig. 2A) and examined the ability of these
chimeras to regulate the expression of the G5E1b-LUC re-
porter in C2C12 and COS-1 cells. The GAL4-NOR-1 chimera
containing the full open reading frame of NOR-1 activated
transcription 10-fold above the control, pGALO (GAL4 DBD),
in muscle and nonmuscle cells (Fig. 2, B and C). The GAL-
NOR-1-AB plasmid, which contains only the AB regions of
NOR-1, with the DBD and LBD deleted, increased transcrip-
tion of the reporter construct 15–20-fold over the GAL-DBD
alone in myogenic cells and nonmuscle cells (Fig. 2, B and C).
This indicated that the AB region of NOR-1 contained an ago-
nist-independent AF-1 domain.
The GAL-NOR-1-DE, which encodes the LBD of NOR-1 with
the AB and C regions deleted, did not activate transcription
(Fig. 2, B and C), which was consistent with the reporter
analysis. This suggested that the LBD lacked an intrinsic and
classical transcriptional domain.
The AB region is composed of 292 amino acids, which encode
the N-terminal AF-1 domain. In order to further characterize
the AF-1 region of NOR-1, we have constructed subregions of
the AB domain by PCR and cloned these segments into the
GAL4-DBD (Fig. 3A). These constructs were transfected into
C2C12 and COS-1 cells and assayed in the GAL4 hybrid system
(Fig. 3, B and C). The constructs GAL-NOR-1-aa-1–150, GAL-
NOR-1-aa40–160, and GAL-NOR-1-aa150–292 were created
and assayed by transfection. These segments of the AB region
of NOR-1 increased activation 20-, 9-, and 7-fold relative to the
control, GAL-DBD alone, in myogenic cells (Fig. 3B). A similar
trend was observed in COS-1 cells (Fig. 3C), although the level
of activation was weaker. This suggested that the AF-1 domain
was located between aa positions 1 and 150 in the AB region.
The plasmid, GAL-NOR-1-aa-150–292, did not trans-activate
gene expression efficiently in this assay system (4–7-fold in
nonmuscle and myogenic cells) (Fig. 3, B and C).
We subsequently constructed GAL-NOR-1-aa-1–60 and
GAL-NOR-1-aa1–112 (Fig. 3A) and assayed these plasmids by
transfection analysis. These segments of the AB region of
NOR-1 increased activation 15- and 42-fold relative to the
GAL4-DBD alone in myogenic cells (Fig. 3B). This delimited
the functional AF-1 domain to between aa positions 1 and 112
in the AB region and showed that the region downstream of aa
position 150 was not necessary for the efficient activity of the
AF-1 domain.
The Steroid Receptor Coactivators SRC-1, -2, and -3 Directly
Interact with NOR-1: The AF-1 Domain Recruits SRC Di-
rectly—The N-terminal AF-1 region and the C-terminal LBD
(containing the imbedded AF-2 domain) of the NOR-1/NR4A3
subgroup are very unusual and have not been demonstrated to
directly interact with coactivators. However, we have demon-
strated that the steroid receptor coactivator, SRC, binds and
modulates the activity of the Nur77/NR4A1 AF-1 domain (68).
Consequently, we examined the ability of the SRCs (SRC-1,
-2, and -3) to directly interact with NOR-1. We tested this
hypothesis using a biochemical approach, the in vitro GST
pull-down assay. Glutathione-agarose-immobilized GST-
NOR-1, GST-NOR-1-AB, and GST-NOR-1-DE were tested for
direct interaction with in vitro 35S-radiolabeled full-length
SRC-1, -2, and -3 (Fig. 4A). We observed that SRC-1, -2, and -3
efficiently interacted with NOR-1. Interestingly, the SRCs di-
rectly interacted with the AB region of NOR-1 that encoded the
AF-1 domain, concordant with the observations with the other
NR4A member, Nur77 (68). In contrast to other nuclear hor-
mone receptors, the DE region that encodes the LBD did not
efficiently interact with the steroid receptor coactivators (Fig.
4A). This is consistent with the NBRE reporter assays and the
GAL4 hybrid analysis (Figs. 1B and 2, B and C).
The NOR-1 LBD Coactivator Binding Cleft Is Unusually
Hydrophilic: Coactivator-derived Peptides Bind Poorly in Dock-
ing Simulations—We used molecular modeling as a tool to
further investigate the inability of the atypical nuclear receptor
LBD to interact with coactivators. The starting point for ho-
mology modeling was the crystal structure of the human RAR.
Alignments were performed with ClustalV and adjusted man-
ually thereafter. Homology modeling was performed by satis-
faction of spatial restraints using the program Modeler 6 (60).
The resulting model was subjected to Ramachandran analysis
FIG. 2. The AB region of NOR-1 encodes a potent AF-1 activa-
tion domain. A, diagrammatic representation of Gal-NOR-1 chimeric
constructs. B and C, GALNOR-1-FL, GAL-NOR-1-AB, and GAL-NOR-
1-DE (0.33 g) were co-transfected with the GAL reporter G5EIb-Luc (1
g) into C2C12 proliferating myoblasts (B) and into COS-1 cells (C).
-Fold activation is expressed relative to luciferase activity obtained
after cotransfection of the Gal4 DNA-binding domain alone, arbi-
trarily set at 1. The mean luciferase -fold activation values and S.D.
(bars) were derived from a minimum of two or three independent
triplicate experiments.
AF-1 Domain of NOR-1/NR4A324780
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
and further quality checking with the WhatIf suite of pro-
grams. Hydrophobicity analysis was performed using the mo-
lecular modeling program SCULPT (61). An LXXLL-containing
peptide from a previously published thyroid hormone receptor/
steroid receptor coactivator peptide complex was superimposed
onto the NOR-1 LBD, enabling us to delineate a hypothetical
coactivator binding interface.
Fig. 4 shows comparative surface views of rROR (a related
nuclear receptor but one that is distinct from the template
structure) (B) and the modeled NOR-1 (C). The rROR surface
is derived from a crystallographic structure of the receptor in
complex with a coactivator peptide (69). Examination of the
molecular surface in the region of the hypothetical coactivator
interfaces shows startling differences in hydrophobicity;
rROR (B) shows the characteristic hydrophobic groove (blue)
found in AF-2-activating receptors, whereas NOR-1 (C) pos-
sesses an unusually hydrophilic surface (red shade). Addition-
ally, there are marked differences in local surface topography
as shown in the close up views (B and C). Docking using
molecular mechanic simulation of a superimposed SRC coacti-
vator peptide from an existing structure suggests that NOR-1
can bind a coactivator peptide. However, this procedure results
in noticeable distortion of the peptide. Peptide distortion to-
gether with differences in the coactivator-binding surface of
NOR-1 prompted us to perform comparative simulations of the
ability of NOR-1 and RAR to bind coactivator peptide de novo
(i.e. without reference to existing coactivator peptide com-
plexes). Simulations were based on iterative docking and frac-
tional rotation, so that 6.3  108 rotational combinations be-
tween coactivator peptide and receptor were sampled with
ranking of the resulting solutions according to docking energy.
When we performed this simulation using the LBD of RAR,
we found that 6 of the 10 highest scoring solutions docked to
within 5 Å root mean square of a coactivator/receptor model
based on superposition of the existing thyroid hormone recep-
tor/GRIP-1 (SRC-2) peptide crystal structure. In contrast, the
best 50 solutions for NOR-1 did not approach to within 5 Å of
the equivalent position (data not shown). However, higher en-
ergy docking solutions did cluster in the area delineated by the
earlier superimposed coactivator peptide. This is most likely
due to the differences in hydrophobicity and topology between
the two interfaces. Given the dominance of the SRC-2/GRIP-1
type LXXLL coactivator peptide in receptor interaction, this
observation may account for the inability of this nuclear recep-
tor LBD to efficiently mediate SRC recruitment in the GST
pull-down assay.
The Steroid Receptor Coactivator, SRC-2, Stimulates the Ac-
tivity of the NOR-1 AF-1 Domain—The process of cofactor re-
cruitment and the interaction of coactivators with NOR-1/
NR4A3 has remained obscure. Since NOR-1 can activate
transcription directly, and we had demonstrated that the SRCs
interact directly with the NOR-1 AF-1, we examined the effect
of SRC-2/GRIP-1 expression on NOR-1-mediated transactiva-
tion in the GAL4 hybrid system. In these assays, the activity of
NOR-1 is independent of its binding to its cognate binding
motifs, the NBRE-3 and NurRE-5POMC response elements. If
SRC-2 regulates the transcriptional activity of NOR-1, then the
potential of the GAL4-NOR-1 fusions to trans-activate gene
expression should be increased in this assay (Fig. 5A). Cells
were cotransfected with GAL-NOR-1, GAL-NOR-1-AB, GAL-
NOR-1-DE, and the G5E1b-LUC reporter in the presence and
absence of an SRC-2 expression vector (Fig. 5B). G5E1b-LUC
contains five copies of the GAL4 binding site placed upstream
of a minimal E1b promoter.
Transfection of GAL-NOR-1 and Gal-NOR-1AB induced
transcription relative to the GAL4 DBD; this level of activity
was significantly stimulated by the addition of SRC-2 by 4-
fold. SRC-2 did not modulate or increase the activity of the
C-terminal LBD (Fig. 5B).
To delimit the region within the AF-1 domain that is modu-
lated by SRC-2, we transfected cells with GAL-NOR-1-aa1–
150, GAL-NOR-1-aa40–160, GAL-NOR-1-aa150–292, in the
presence and absence of SRC-2. We observed that GAL-NOR-
FIG. 3. The activation domain within the AB region is located
between amino acid positions 1 and 112. A, diagrammatic repre-
sentation of Gal-NOR-1 chimeric constructs. B and C, GAL-NOR-1-AB,
GAL-NOR-1-aa1–150, GAL-NOR-1-aa40–160, GALNOR-1-aa150–292,
GAL-NOR-1-aa1–60, and GAL-NOR-1-aa1–112 chimeras (0.33 g)
were cotransfected with the GAL4-dependent reporter G5E1B-Luc (1
g) into C2C12 proliferating myoblasts (B) and COS-1 cells (C). -Fold
activation is expressed relative to luciferase activity obtained after
cotransfection of the Gal4 DNA-binding domain alone, arbitrarily set
at 1. The mean luciferase -fold activation values and S.D. values
(bars) were derived from a minimum of two or three independent
triplicate experiments.
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1-aa1–150, and GAL-NOR-1-aa40–160 were efficiently stimu-
lated 7-fold by co-expression of SRC-2. However, GAL-NOR-
1-aa150–292 was not stimulated by SRC-2. This suggested
that SRC-2 modulates the activity of the N-terminal AF-1
domain in NOR-1, and this coactivation is dependent on the
region between aa positions 40 and 160 in the AB region (Fig.
5C). Additionally, we examined the ability of SRC-2 to stimu-
late GAL-NOR-1-aa1–60 and GAL-NOR-1-aa1–112 in an effort
to further delimit the SRC-2-responsive domain (Fig. 5D). Al-
though we observed that these chimeras were modulated by
SRC-2, the most efficient modulation by SRC-2 was mediated
by the domain between aa positions 40 and 160.
The Nuclear Hormone Receptor Cofactors SRC, p300, PCAF,
and DRIP205/TRAP220 Directly Interact with NOR-1: The
AF-1 Domain Can Recruit a Co-activator Complex—Our stud-
ies had demonstrated the direct binding of SRCs to NOR-1 and
the modulation of AF-1 activity by SRC-2. Activation of gene
expression by the classical nuclear hormone receptors is de-
pendent on the recruitment of SRC-1, -2, and -3. These SRCs
recruit p300/CREB-binding protein and PCAF to synergisti-
cally activate transcription. SRCs, CREB-binding protein/
p300, and PCAF possess intrinsic histone acetyltransferase
activity and act in concert to remodel the chromatin. This
complex results in the assembly of a higher order structure
that includes the “DRIP-TRAP-ARC” protein complex that reg-
ulates localized nucleosome structure (as reviewed in Ref. 70).
The key member of this complex is DRIP205-TRAP220.
To further investigate cofactor recruitment, we examined the
FIG. 4. SRCs directly interact with
NOR-1: The AF-1 domain recruits
SRC directly. A, glutathione agarose-
immobilized GST, GST-NOR-1, GST-
NOR-1-AB, and GST-NOR-1-DE were in-
cubated independently with in vitro 35S-
radiolabeled full-length SRC-1, SRC-2,
and SRC-3, respectively. The input lane
represents 10% of the total protein. B
and C, the NOR-1 LBD coactivator bind-
ing cleft is unusually hydrophilic; coacti-
vator-derived peptides bind poorly on
docking simulations. B and C, hydropho-
bic and surface topography analysis of
ROR (B) and NOR-1 (C) molecular sur-
faces. Surfaces were defined by a probe
with a radius of 1.4 Å using SCULPT 3.0.
Hydrophobic areas are colored blue,
whereas hydrophilic areas are colored
red. SRC-2 (GRIP-1) coactivator peptide
from a previously published structure has
been superimposed to delineate an ap-
proximate coactivator binding area.
Leucines from the coactivator peptide are
depicted in stick form, colored pink. A sig-
nificant reduction in hydrophobicity is ap-
parent in the NOR-1 LBD coactivator in-
terface region when compared with a
similar area of ROR (C). Additionally,
the surface topography is different in this
region despite the similarity in backbone
conformation.
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ability of p300, DRIP205, and PCAF to interact with NOR-1.
Glutathione-agarose-immobilized GST-NOR-1, GST-NOR-1-
AB, and GST-NOR-1-DE were tested for direct interaction with
in vitro 35S-radiolabeled full-length p300, DRIP205, and PCAF.
We observed that p300, DRIP205, and PCAF very efficiently
interacted with native NOR-1 (Fig. 6A, lanes 7–9). In contrast,
the discrete N- and C-terminal regions of NOR-1 that encoded
the NOR-1-AB and NOR-1-DE domains, respectively, sup-
ported weak but significant recruitment of p300. The specificity
of the weak p300 interaction was demonstrated by the lack of
DRIP205 binding to the N-terminal AB region (Fig. 6A, lane
11). However, the C-terminal DE region (i.e. the LBD) of
NOR-1 could support the efficient recruitment of DRIP205 (Fig.
6A, lane 14). PCAF interacted efficiently with native NOR-1
and the individual NOR-1-AB and NOR-1-DE regions (Fig. 6A,
lanes 9, 12, and 15). These data and the previous binding data
with SRC-2 demonstrate that the N-terminal AB region is
necessary for cofactor recruitment.
As described, SRC-2 independently and efficiently interacted
with the AB region of NOR-1; furthermore, it stimulated the
activity of the AF-1 domain (see Figs. 4 and 5). Hence, we
investigated the relative recruitment of p300 and SRC-2 to the
AF-1 domain. Furthermore, we investigated whether the AF-1
domain encoded by the AB region mediated DRIP205 recruit-
ment in the presence of p300 and SRC-2. We observed that
SRC-2 bound more efficiently than p300 to GST-NOR-1-AB
(Fig. 6B, lane 5 versus lane 7). Moreover, in the presence of
SRC-2 and p300, the N-terminal region could recruit DRIP205
(Fig. 6B, lane 8 versus lane 6). The specificity of the AF-1-
mediated DRIP205 recruitment was verified by the lack of
binding in the absence of the primary coactivators, SRC-2 and
p300 (Fig. 6B, lane 6). Neither SRC-2 nor p300 independently
mediated the recruitment of DRIP205 to the N-terminal AB
region (Fig. 6C, lanes 9 and 10, relative to the GST control in
lane 4). These studies suggested that the AF-1 domain of
NOR-1 supports the recruitment of DRIP205 in the presence of
the primary cofactors, SRC-2 and p300.
We extended these studies to compare the relative ability of
native NOR-1 and the discrete AB and DE regions to recruit
and interact with the coactivator complex. We observed that
GST-NOR-1 and GST-NOR-1-AB could simultaneously and ef-
ficiently pull down SRC, DRIP205, p300, and PCAF (Fig. 6C,
FIG. 5. SRC-2 potentiates the activity of the NOR-1-AB region. A, a diagrammatic representation of the Gal4 hybrid assay is shown. This
assay was used to determine the effect of SRC-2/GRIP-1 expression on NOR-1-mediated transactivation of gene expression. 0.33 g of GAL-NOR-
1-FL, GAL-NOR-1-AB, GAL-NOR-1-DE (B), 0.33 g of GAL-NOR-1-aa1–150, GAL-NOR-1-aa40–160, GAL-NOR-1-aa150–292 (C), 0.33 g of
GAL-NOR-1-aa1–60, GAL-NOR-1-aa1–112 (D) were co-transfected with the GAL4-dependent reporter G5E1B-Luc (1 g) into COS-1 cells in the
presence and absence of the co-transfected expression plasmid encoding SG5-SRC-2 (0.66 g). -Fold activation is expressed relative to luciferase
activity obtained after cotransfection of the Gal4 DNA-binding domain alone, arbitrarily set at 1. The mean luciferase -fold activation values and
S.D. values (bars) were derived from a minimum of two or three independent triplicate experiments.
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lanes 6 and 7). In contrast, the DE region that encodes the LBD
less efficiently interacted with this complex (Fig. 6C, lane 8).
These studies suggested that the AF-1 domain of NOR-1 can
independently and efficiently mediate the recruitment of the
coactivator complex, which is consistent with the intrinsic tran-
scriptional activity of the AF-1 domain.
The N-terminal AB Region Directly Interacts with the C-
terminal LBD: The Interaction Is Potentiated by AF-1-mediated
Recruitment of SRC—It has been previously demonstrated that
human SRC-2 concomitantly interacts with the estrogen recep-
tor AF-1 and AF-2 to syngergistically regulate transcription
(71–73). Our studies suggested that SRC-2 preferentially in-
teracts with the NOR-1 AF-1 but not the C-terminal LBD. We
investigated whether the atypical role of the NOR-1 LBD in
transcriptional activation involved intramolecular interactions
with the N-terminal AF-1 and whether this process was mod-
ulated by SRC recruitment (Fig. 7A).
We tested this hypothesis using a biochemical approach, the
in vitro GST pull-down assay. Glutathione-agarose-immobi-
lized GST-NOR-1-AB was tested for direct interaction with in
vitro 35S-radiolabeled full-length SRC-2 and the NOR-1 LBD
(CDE) (Fig. 7B). As expected from our studies above, we ob-
served that SRC-2 efficiently interacted with the NOR-1-AB
(Fig. 7B, lane 5). Very interestingly, we observed that the
N-terminal AB region that encodes the potent AF-1 domain
interacts more efficiently with the C-terminal LBD region in
the presence of SRC-2 (Fig. 7B, lane 6 versus lane 8). The
coactivator p300 did not potentiate this interaction in an effi-
cient manner (Fig. 7B, lane 7). This evidence clearly demon-
strates intramolecular interactions between the N-and C-ter-
minal regions of NOR-1 and provides evidence for the
involvement of the NOR-1 LBD in the absence of an intrinsic
activation function. In summary, this suggests that SRC-2
potentiates the direct interaction between the N-terminal AF-1
domain and the C-terminal LBD region of NOR-1.
The Antileukemic Hypoxanthine Analog 6-Mercaptopurine
Regulates NR4A1–3-mediated Trans-activation—In 2002, Hey-
man (87) presented data demonstrating that the purine anti-
metabolite 6-mercaptopurine (and some related compounds)
activated the trans-activation of the NurREPOMC reporter by
NR4A2/Nurr1 in CV-1 cells. We examined the ability of 6-MP
to activate Nurr1-, NOR-1-, and Nur77-mediated trans-activa-
tion of the NurREPOMC reporter in myogenic cells. We cotrans-
fected the NurREPOMC reporter with expression vectors encod-
ing the three members of the NR4A family into mouse muscle
cells cultured in phenol red-free DMEM supplemented with 5%
charcoal-stripped fetal bovine serum. We observed that 6-MP
induced the Nurr1-, NOR-1-, and Nur77-mediated trans-acti-
vation of the NurREPOMC reporter (Fig. 8, A–C). Furthermore,
the 6-MP-activated NOR-1-mediated trans-activation was com-
promised by the deletion of either the C-terminal LBD or N-
terminal AB region (Fig. 8B). This suggested that the purine
anti-metabolite activated all members of the NR4A subgroup.
The AF-1 Domain of NOR-1 Mediated Activation by 6-Mer-
captopurine—To identify the domain of NOR-1 that mediated
6-MP activation, we utilized our series of GAL-NOR-1 dele-
tions. We investigated the ability of 6-MP to modulate the
activity of GAL-NOR-1, GAL-NOR-1-AB, and GAL-NOR-1-DE.
These experiments clearly demonstrated that 6-MP potently
modulated the activity of NOR-1. Moreover, the data clearly
demonstrated that the N-terminal AB region, which encodes
of the total protein. D, GST (lane 5), GST-NOR-1 (lane 6), GST-NOR-
1-AB (lane 7), and GST-NOR-1-DE (lane 8) were incubated simulta-
neously with in vitro 35S-radiolabeled full-length p300, DRIP205,
SRC-2, and PCAF. The input lanes (lanes 1–4) represent 10% of the
total protein.
FIG. 6. The nuclear hormone receptor cofactors SRC, p300,
PCAF, and DRIP205-TRAP220 directly interact with NOR-1: The
AF-1 domain can recruit a co-activator complex. A, glutathione-
agarose-immobilized GST (lanes 4–6), GST-NOR-1 (lanes 7–9), GST-
NOR-1-AB (lanes 10–12), and GST-NOR-1-DE (lanes 13–15) were in-
cubated independently with in vitro 35S-radiolabeled full-length p300,
DRIP205, and PCAF, respectively. The input lanes (lanes 1–3) repre-
sents 10% of the total protein. B, GST (lane 4) and GST-NOR-1-AB
were incubated independently (lanes 5–7) or simultaneously (lane 8)
with in vitro 35S-radiolabeled full-length p300, DRIP205, and SRC-2.
The input lanes (lanes 1–3) represent 10% of the total protein. C, GST
(lane 4) and GST-NOR-1-AB were incubated independently (lanes 5–7)
or simultaneously (lanes 8–10) with in vitro 35S-radiolabeled full-length
p300, DRIP205, and SRC-2. The input lanes (lanes 1–3) represent10%
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the AF-1 domain of NOR-1, mediated 6-MP activation. This
experiment ruled out the possibility that 6-MP activation in-
volved the modulation of DNA binding or LBD activation
(Fig. 9A).
The specificity and selectivity of the 6-mercaptopurine com-
pound have been examined by the Heyman group at X-ceptor
Therapeutics.2 This compound does not activate other nuclear
hormone and orphan receptors. Hence, we investigated
whether 6-MP activated general trans-activators (GAL4VP16),
myogenic trans-activators (MyoD, myogenin, MEF2C, and
MEF2D), and the primary coactivators, SRC-2 and p300. We
observed that 6-MP did not selectively activate other transcrip-
tion factors and coactivators in muscle cells (Fig. 9, B and C).
There were minor inductions of 1.5–3-fold; however, relative to
the nonspecific effects on GAL4 (1–1.7-fold) and 20-fold ef-
fects on NOR-1, these changes were insignificant.
Potential phosphorylation sites in the N-terminal region of
the NR4A family surrounding amino acid positions 50 and 142
have been implicated in the control of subcellular localization,
AF-1 activity, and modulation by several kinases (e.g. Erk2,
Trk, Ras, and mitogen-activated protein kinase) (13, 74, 75).2 P. Ordentlich and R. Heyman, personal communication.
FIG. 7. The N-terminal AB region directly interacts with the
C-terminal LBD: The interaction is potentiated by AF-1-medi-
ated recruitment of SRC. A, a diagrammatic representation of the
intramolecular interaction between AF-1 and AF-2 of NOR-1 that is
potentiated by AF-1-mediated recruitment of SRC-2. B, GST (lane 3)
was incubated simultaneously with in vitro 35S-radiolabeled p300,
SRC-2, and NOR-1-CDE and GST-NOR-1-AB (lanes 4–6) were incu-
bated independently with in vitro 35S-radiolabeled p300, SRC-2, and
NOR-1-CDE, respectively, and GST-NOR-1-AB (lane 7) was incubated
simultaneously with in vitro 35S-radiolabeled p300, and NOR-1-CDE
and GST-NOR-1-AB (lane 8) were incubated simultaneously with in
vitro 35S-radiolabeled SRC-2 and NOR-1-CDE. The input lane repre-
sents 10% of the total protein.
FIG. 8. The antileukemic hypoxanthine analog 6-mercaptopu-
rine regulates NR4A1–3-mediated transcription. A, pCMX-
NURR1-FL (0.33 g) was co-transfected into C2C12 proliferating myo-
blasts together with the reporter gene NurRE-5-tk-Luc in the presence
and absence of 50–100 M 6-MP. B, SG5-NOR-1-FL, SG5-NOR-1-CDE,
and SG5-NOR-1-ABC (0.33 g) were co-transfected into C2C12 prolifer-
ating myoblasts together with the reporter gene NurRE-5-tk-Luc in the
presence and absence of 50 M 6-MP. C, pCMX-Nur77-FL, (0.33 g) was
co-transfected into C2C12-proliferating myoblasts together with the re-
porter gene NurRE-5-tk-Luc in the presence and absence of 50–100 M
6-MP. -Fold activation is expressed relative to luciferase activity obtained
after cotransfection of the pCMX or pSG5 alone, arbitrarily set at 1. The
mean luciferase -fold activation values and S.D. values (bars) were de-
rived from a minimum of two or three independent triplicate experiments.
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We constructed two double mutants in both regions to investi-
gate the effect of mutation on potential phosphorylation sites
and 6-MP-mediated activation. We observed that both double
mutants GAL-NOR-1 S59P/T60P and GAL-NOR-1 S142P/
T145P did not compromise the ability of 6-MP to modulate the
activity of NOR-1/NR4A3 (Fig. 10).
The Minimal Region between Amino Acid Residues 1 and 150
Mediated 6-MP Activation: Other Thiopurine Compounds Acti-
vated NOR-1—We utilized our comprehensive set of GAL-
NOR-1-AB deletions to identify the minimal region that medi-
ates 6-MP activation. We observed that the domain between
amino acids 1 and 150 retained the potential to be activated
significantly by 6-MP. The C-terminal region of the AF-1 do-
main between amino acids 150 and 292 was completely dispen-
sable for 6-MP activation. Although the region between amino
acid residues 1 and 60 retained 6-MP inducibility, it was con-
siderably compromised (Fig. 11A).
We examined the ability of several other thiopurine com-
pounds including 6-mercaptopurine riboside (6-MP-R), 6-mer-
captopurine deoxyriboside (6-MP-deoxy-R), 6-mercaptopurine
monohydrate (6-MP-mh), and 6-mercaptopurine ribofurano-
side (6-MP-RF) to activate NOR-1. Interestingly, all of these
thiopurine compounds efficiently activated the N-terminal re-
gion of NOR-1 (Fig. 11B).
DISCUSSION
In this investigation, we have provided evidence that NOR-1
trans-activates gene expression in a cell- and target-specific
manner. Moreover, the AB region was necessary for optimal
NOR-1-dependent trans-activation and encodes an N-terminal
FIG. 9. 6-MP modulates the activity of NOR-1 AF-1 domain. A,
GAL-NOR-1-FL, GAL-NOR-1-AB, and GAL-NOR-1-DE (0.33 g) were
co-transfected with the GAL reporter G5EIb-Luc (1 g) into C2C12 pro-
liferating myoblasts in the presence and absence of 50 M 6-MP. B,
GAL4VP16, GAL-MEF2C, GAL-MEF2D, GAL-MyoD, and GAL-Myoge-
nin (0.33 g) were co-transfected with the GAL reporter G5EIb-Luc (1 g)
into C2C12 proliferating myoblasts in the presence and absence of 50 M
6-MP. C, GAL-SRC-2 and GAL-p300N-ter (0.33 g) were co-transfected
with the GAL reporter G5EIb-Luc (1 g) into C2C12 proliferating myo-
blasts in the presence and absence of 50 M 6-MP. -Fold activation is
expressed relative to luciferase activity obtained after cotransfection of
the Gal4 DNA-binding domain alone, arbitrarily set at 1. The mean
luciferase -fold activation values and S.D. values (bars) were derived from
a minimum of two or three independent triplicate experiments.
FIG. 10. NOR-1 mutants did not compromise the ability of
6-MP to modulate the activity of NOR-1. Shown is a schematic
comparison of the amino acid sequence of mouse Nur77, NOR-1, and
NURR1. *, potential phosphorylation sites. GAL-NOR-1-AB, GAL-
NOR-1-S59P/T60P, and GAL-NOR-1-S142P/T145P were co-transfected
with the GAL reporter G5EIb-Luc (1 g) into C2C12 proliferating
myoblasts in the presence and absence of 50 M 6-MP. -Fold activation
is expressed relative to luciferase activity obtained after cotransfection
of the Gal4 DNA-binding domain alone, arbitrarily set at 1. The mean
luciferase -fold activation values and S.D. values (bars) were derived
from a minimum of two or three independent triplicate experiments.
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AF-1 domain between amino acids 1 and 112, which is neces-
sary for the activation of gene expression. Interestingly, the
N-terminal AB region (not the LBD) is essential for the recruit-
ment of the coactivator complex. Additionally, we demonstrate
that SRC-2 (i) modulates the activity of the N-terminal AF-1
domain, (ii) interacts efficiently with the N-terminal AB region,
FIG. 11. The region between amino acid residues 1 and 150 mediated 6-MP activation: Other thiopurine compounds activated
NOR-1. A, GAL-NOR-1-AB, GAL-NOR-1-aa1–60, GAL-NOR-1-aa1–112, GAL-NOR-1-aa40–160, GAL-NOR-1-aa1–150, and GAL-NOR-1-aa150–
292 chimeras (0.33 g) were cotransfected with the GAL4-dependent reporter G5E1B-Luc (1 g) into C2C12 proliferating myoblasts in the
presence and absence of 50 M 6-MP (B). GAL-NOR-1-AB (0.33 g) was cotransfected with the GAL4-dependent reporter G5E1B-Luc (1 g) into
C2C12 proliferating myoblasts in the presence and absence of 50 M 6-MP, 6-mercaptopurine riboside (6-MP-R), 6-mercaptopurine deoxyriboside
(6-MP-deoxyR), 6-mercaptopurine monohydrate (6-MP-mh), and 6-mercaptopurine ribofuranoside (6-MP-RF), respectively. -Fold induction is
expressed as the -fold activation obtained from cotransfection of the GAL-NOR-1 chimeras in the presence of 6-MPs relative to the -fold activation
obtained from cotransfection of GAL-NOR-1 chimeras in the absence of 6-MPs. The mean luciferase -fold induction values and S.D. values (bars)
were derived from a minimum of two or three independent triplicate experiments.
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and (iii) potentiates the physical association of the N-terminal
AF-1 domain with the C-terminal LBD of NOR-1.
Intriguingly, we demonstrated that the purine anti-metabo-
lite 6-mercaptopurine (and other 6-MP thiopurine variants),
which has antiproliferative, anti-cancer, and anti-inflamma-
tory properties, activated Nur77-, Nurr1-, and NOR-1-medi-
ated trans-activation of gene expression in muscle cells. This
implicates the NR4A subgroup as potential mediators of 6-MP-
mediated antiproliferative effects. Surprisingly, the data dem-
onstrated that the N-terminal AF-1 domain of NOR-1 mediated
the 6-MP activation and not the C-terminal LBD. This was
consistent with the in vitro binding data and the identification
of the N-terminal trans-activation domain. The results imply
that the AF-1 domain plays a hierarchical role in NOR-1-
mediated transcriptional activation and is the target of com-
pounds that induce genotoxic stress by the inhibition of de novo
purine biosynthesis and nucleic acid misincorporation of thio-
purines into nucleic acids.
Surprisingly, the N-terminal AF-1 domain was necessary for
cofactor recruitment and 6-MP-mediated activation. Although
the LBD independence was atypical of NRs, NOR-1 retained
the classical domain-dependent coupling of ligand dependent
modulation and coactivator binding. This suggests that both
AF-1 and AF-2 domains are the targets of agonist-dependent
regulation and interfaces for cofactor binding.
The NOR-1 N-terminal AB region encodes an AF-1 domain,
which is directly bound and modulated by SRC-2/GRIP-1. In
contrast to other nuclear hormone receptors, the DE region
that encodes the LBD did not efficiently interact with the SRC
factors and other members of the coactivator complex. How-
ever, the NOR-1-AB region supported the efficient recruitment
of the coactivator complex including SRC-2, p300, PCAF, and
DRIP205. Furthermore, the AF-1 domain is necessary for the
formation of the coactivator complex and provides one expla-
nation for the atypical nature of NR4A-mediated trans-activa-
tion. Interestingly, the AF-1-mediated recruitment of SRC-2
promotes intramolecular interactions with the LBD that may
function to stabilize the receptor-coactivator complex during
transcriptional activation and/or facilitate agonist dependent
regulation. This observation provided justification for (i) the
loss of activity after deletion of the C-terminal helix 12 in the
LBD and (ii) the requirement of the LBD for optimal 6-MP/
NOR-1-mediated transactivation of the NurREPOMC, although
the NOR-1 LBD does not encode an activation domain per se.
Our molecular modeling analysis of the NR4A3/NOR-1 C-
terminal LBD region suggests that the topology of the orphan
LBD prevents efficient coactivator recruitment. Examination
of the molecular surface in this region shows an unusually
hydrophilic surface, which is in contrast to the archetypal and
characteristic hydrophobic groove found in AF-2-activating re-
ceptors (e.g. RAR and thyroid hormone receptor). Computer
modeling demonstrates that the NOR-1 LBD is able to bind a
coactivator-derived peptide. However, binding results in signif-
icant distortion of the motif due to the differences in hydropho-
bicity and topology between the NOR-1 and classical NRs.
Additionally, the ability of our NOR-1 model to dock with
coactivator peptides in de novo simulations is appreciably com-
promised when compared with receptors that are known to
bind SRC type coactivator peptides. These observations are
also consistent with the observation that the AF-2 core regions
in the ligand-dependent receptors (e.g. RAR and RXR) contain
a very highly conserved glutamic acid. This glutamic acid is
important for cofactor recruitment and transcriptional activa-
tion in classical NRs (76); in contrast, the NR4A subgroup
(Nur77, Nurr1, and NOR-1) has a conserved lysine.
6-MP regulates the activity of NOR-1 in an AF-1-dependent
manner. This thiopurine compound is a small molecule widely
used for the treatment of acute lymphoblastic leukemia,
chronic myelocytic leukemia, and autoimmune/inflammatory
disorders (e.g. Crohn’s disease) (77–79). 6-MP belongs to a class
of nucleic acid analogs that selectively block de novo nucleotide
synthesis in rapidly proliferating cells. This purine anti-metab-
olite has antiproliferative and cytotoxic effects resulting pri-
marily from the inhibition of purine biosynthesis at multiple
steps and incorporation into nucleic acids as thioguanine nu-
cleotides (80).
6-MP is metabolized into the active derivative, 6-thioinosine
monophosphate, by hypoxanthine-guanine phosphoribosyl-
transferase, a key enzyme involved in the purine salvage path-
way. The 6-thio-IMP can be metabolized into 6-thioguanosine
5-monophosphate, which is than incorporated into DNA and
RNA as 6-thioguanosine triphosphate (6-thio-GTP) resulting in
eventual cytotoxicity and cell death (80). Incorporation of
6-thio-GTPs into nucleic acids is thought to be the main mech-
anism of action.
At this point, the 6-thio-IMP can be utilized in two different
pathways. One option is that the 6-thioinosine monophosphate
can be methylated by thiopurine methyltransferase to methyl
mercaptopurine riboside phosphate, which is a potent inhibitor
of de novo purine biosynthesis at the level of phosphoribosylpy-
rophosphate aminotransferase, which depletes the intracellu-
lar ATP pools. Thiopurine methyltransferase also converts
6-MP into methylmercaptopurine, which has no cytotoxic ac-
tivity. The majority of the known functions of 6-MP involve
conversion into the active metabolite 6-thio-IMP through the
enzyme hypoxanthine-guanine phosphoribosyltransferase (80).
However, 6-MP also leads to DNA hypomethylation, which can
effect gene expression.
The antiproliferative activity of 6-MP has been also shown to
result partly from a decrease in the production of adenosine
and guanosine synthesis (80). It should be noted that control of
adenosine pools can regulate levels of AMP/ADP/ATP available
to carry out cellular functions. This would imply that there
exists the possibility of an ATP-dependent pathway that can
regulate NOR-1 (NR4A3) activity. Indeed, recent reports sug-
gest that a cAMP-dependent protein kinase A signaling cas-
cades can regulate both NR4A subgroup expression and tran-
scription activity (81, 82). Serine/threonine-rich domains in the
N terminus have been implicated in the regulation of NR4A1/
Nur77-dependent transcription (13, 74, 75). Moreover, phos-
phorylation of amino acid residues in the AB region have been
implicated in growth factor-dependent nucleocytoplasmic shut-
tling and modulation of activity by Erk2, Trk, Ras, and mito-
gen-activated protein kinase (13, 74, 75). Furthermore, regula-
tory phosphorylation sites have been identified in the DNA
binding domain of NR4A1/Nur77. For example, Akt kinase, a
key player in the transduction of antiapoptotic and prolifera-
tive signals in T cells, phosphorylates Ser-350 and decreases
the transcriptional activity of Nur77/NR4A1 (83, 84). There-
fore, a potential mechanism for NR4A activation by 6-MP may
include regulation of kinase or phosphatase pathways. How-
ever, mutation of the serine and threonine residues at amino
acid positions 54, 55, 142, and 145 in the phosphorylation
motifs that had been implicated in kinase-dependent regula-
tion targets did not compromise the ability of 6-MP to
activate NOR-1.
The ability of 6-MP to regulate the activity of a transcription
factor class, such as the NR4A subgroup, considerably broad-
ens the possible mechanism of action of this drug. NR4A sub-
group expression and tissue distribution in leukemic cells and
inflammatory disease indicate that members of this family are
likely to be present in the tissues targeted by 6-MP. Whereas
AF-1 Domain of NOR-1/NR4A324788
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
many of the steps involved in 6-MP-mediated cytotoxicity have
been elucidated, it is possible that these effects can be en-
hanced or suppressed through secondary targets. NOR-1 has
been shown to play a role in T-cell antigen receptor and calci-
um-mediated apoptosis, cell death, and thymocyte selection in
T lymphocytes (14–16, 44). Additionally, NOR-1 translocation
to the Ewing’s sarcoma gene has been implicated in extraskel-
etal myxoid chondrosarcoma (45).
It has not been directly demonstrated that the regulation of
apoptosis by the NR4A subgroup is through transcriptional
mechanisms. However, we speculate that the effectiveness of
6-MP treatment and the antiproliferative effects may be influ-
enced by the activity of these receptors. Apoptosis represents
an effective way to eliminate cancerous cells, and a variety of
evidence suggests that the NR4A subgroup is involved in the
regulation of apoptosis in prostate, lung, gastric, breast, and
colon cancer cells (28–34).
Supporting evidence for this hypothesis includes the follow-
ing. (i) NOR-1 expression is regulated by Ca2/calmodulin-de-
pendent protein kinases and inflammatory cytokines. (ii) Gene
targeting experiments have established a role for NOR-1 and
Nur77 in mediating T cell development. Furthermore, Nur77
and NOR-1 are rapidly induced by the T-cell antigen receptor
and Ca2 signaling in immature thymocytes, leading to apop-
tosis (14–17, 44). (iii) T-cell chronic lymphocytic/prolympho-
cytic leukemia is associated with increased Akt kinase activity
(41, 42, 43, 85, 86), which transduces antiapoptotic and prolif-
erative signals in T cells. Moreover, Akt phosphorylates serine
in the DBD of the NR4A subgroup to inhibit binding/function.
The other related thiopurine compounds 6-MP riboside,
6-MP deoxyriboside, 6-MP-monohydrate, and 6-MP ribofurano-
side all efficiently activated the N-terminal region of NOR-1,
suggesting that the signaling pathways that regulate cell pro-
liferation via de novo purine and nucleic acid biosynthesis are
involved in the regulation of NR4A activity. The findings pre-
sented here suggest that there exists in the cell a signaling
cascade that is sensitive to direct regulation by 6-MP, levels of
purine nucleotides, and/or nucleic acid misincorporation. We
hypothesize that the NR4A subgroup mediates the genotoxic
stress response and suggest that this subgroup may function as
sensors that respond to genotoxicity.
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